🧴 JAK Inhibitor for Eczema Simulator

Selective JAK1 Inhibition — Rinvoq & Cibinqo

Both drugs plug the JAK1 ATP-binding pocket to stop cytokine signal relay.

• JAK1: Upadacitinib target (Rinvoq, selective)
• JAK1: Abrocitinib target (Cibinqo, selective)
• IL-4/13/31: Key cytokines blocked (Th2 + itch axis)
• Oral daily: Dosing (once-daily pill)

Mechanism snapshot

Short placeholder: JAK1 blockade halts STAT phosphorylation cascade.

Placeholder callout: selectivity for JAK1 limits off-target cytokine effects.

Itch Control Within Days

Pruritus NRS scores fall noticeably within the first days of therapy.

• ~2 days: Itch drop onset (placeholder timing)
• ~50%: NRS reduction wk1 (placeholder estimate)
• topical steroids: Faster than (placeholder comparison)
• IL-31 blockade: Driven by (nerve signaling axis)

Itch timeline

Short placeholder: itch relief precedes visible skin clearance.

Placeholder callout: rapid itch relief improves sleep and quality of life early.

EASI Clearance Over the Treatment Course

Skin clearance builds progressively across weeks of continued dosing.

• ~65%: EASI-75 by wk16 (placeholder estimate)
• ~wk12–16: Response plateau (placeholder timing)
• yes: Dose-dependent (higher dose, faster clearance)
• continued dosing: Maintenance (placeholder)

Clearance trajectory

Short placeholder: clearance curve rises steadily then plateaus.

Placeholder callout: sustained blockade needed to maintain clearance.

CBC, Lipid and Liver Enzyme Surveillance

Routine labs track cytopenia, lipid shifts and hepatic enzyme changes.

• baseline+periodic: CBC schedule (placeholder cadence)
• wk4, then periodic: Lipid panel (placeholder cadence)
• periodic: LFTs (placeholder cadence)
• lymphopenia, LDL rise: Key flags (placeholder)

Monitoring cadence

Short placeholder: labs checked at baseline and on a periodic schedule.

Placeholder callout: dose adjustment or hold considered on abnormal labs.

Weighing Benefit vs Boxed-Warning Risk

Refractory eczema cases weigh fast control against class safety warnings.

• yes: Boxed warning (JAK class label)
• refractory AD: Typical use (after other therapies)
• CV, clot, malignancy: Risk categories (placeholder class risks)
• required: Shared decision (patient-clinician discussion)

Decision framework

Short placeholder: benefit-risk assessed per patient before starting.

Placeholder callout: reserved for patients failing other systemic options.